Alzamend Neuro Net Loss Widens 75% to $5.9M in Nine Months Ending January 2026

Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company developing treatments for neurological disorders, posted a net loss of $5.90 million for the nine months ending January 31, 2026, compared with a net loss of $3.38 million in the same period a year earlier. The company reported no revenue for either period. Read more earnings reports.

Operating expenses climbed to $5.90 million from $3.36 million, a 76% increase driven primarily by research and development spending. R&D expenses totaled $3.20 million, more than triple the $964,771 recorded in the prior-year period. For the three months ending January 31, 2026, the net loss was $2.20 million, compared with $1.04 million a year earlier.

Cash and cash equivalents stood at $2.71 million as of January 31, 2026, down from $3.95 million at the end of the fiscal year on April 30, 2025. The company burned through $5.27 million in operating cash during the nine-month period, slightly better than the $5.88 million outflow in the prior year. Cash from financing activities totaled $4.04 million, compared with $8.95 million in the earlier period.

Total liabilities jumped to $1.86 million as of January 31, 2026, from $634,761 at April 30, 2025. Stockholders' equity fell to $2.18 million from $3.97 million over the same span. The company's share count expanded dramatically, with 3.80 million common shares outstanding at January 31, 2026, compared with 778,733 at the prior fiscal year-end.

Loss per share for the nine months was $1.89, compared with $9.54 in the prior-year period. The improvement in per-share losses reflects the significant increase in weighted average shares outstanding, which rose to 3.12 million from 362,863. Total assets declined to $4.04 million from $4.60 million at April 30, 2025.